Document is current
Any future updates will be listed below
-
Authors
Torlot, Lucien
Jarzab, Anna
Albert, Johanna
Pók-Udvari, Ágnes
Stahler, Arndt
Holch, Julian Walter
Gerlinger, Marco
Heinemann, Volker
Klauschen, Frederick
Kirchner, Thomas
Kumbrink, Jörg
Küster, Bernhard
Jung, Andreas https://orcid.org/0000-0001-5270-9108
-
Funding
Funding for this research was provided by:
Universitätsklinik München
- License Information
-
More Information
Article History
Received: 10 December 2021
Accepted: 11 October 2022
First Online: 19 November 2022
Declarations
:
: JK received honoraria and reimbursement for travel and accommodation for participation in advisory boards and from speaker's bureau from AstraZeneca, Novartis, Quality Initiative in Pathology (QuIP) and Roche Pharma. AS received honoria by Roche and reimbursements for travel by Amgen, Roche Pharma, Pfizer, and MSD Sharp Dohme. JWH served on an advisory board for Roche, has received honoraria from Roche, and travel support from Novartis. FK received honoraria and reimbursement for travel as well as accommodation for participation in advisory boards or from speaker's bureau from Roche, Novartis, BMS, Merck, Lilly, Agilent, Iomedico and is co-founder of Aignostics GmbH. BK is co-founder and shareholder of OmicScouts GmbH and msAId, but has no operational role in either company. AJu received honoraria and reimbursement for travel as well as accommodation for participation in advisory boards or from speaker's bureau from Amgen, AstraZeneca, Biocartis, Bristol-Myers Squibbs (BMS), Boehringer Ingelheim, Chinese Society for Pathology, German Society for Pathology, European Association for Cancer Research (EACR), International Association for Pathology (IAP), Merck-Serono, Merck-Sharp Dohme (MSD), Quality Initiative in Pathology (QuIP), and Roche Pharma and Takeda.
